CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 63 enrolled
Drug / intervention
Adjuvanted Multimeric-001 250 Mcg +6 morebiological
Likely dose
Adjuvanted Multimeric-001 250 Mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00877448
NCT00877448Phase 2Completed
CompareCT.gov

A Phase I/II, Randomized, Single-Blind, Placebo-Controlled Escalating Double-Dose Safety Study of an Intramuscular Influenza Vaccine (Multimeric-001) Injected to Healthy Volunteers

BiondVax Pharmaceuticals ltd.·interventional·Posted Apr 7, 2009·Updated Mar 7, 2023

In Brief

A Phase 2 clinical trial evaluating Adjuvanted Multimeric-001 250 Mcg, Multimeric-001 250 Mcg, and 5 other interventions for Healthy. Completed, enrolled 63 participants across 1 site.

Detailed Summary

A phase I/II, randomized, single-blind, placebo-controlled escalating double-dose safety study of an intramuscular universal influenza vaccine (Multimeric-001) injected to healthy volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesIsrael
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 7, 2009
Enrollment StartJun 1, 2009
Primary CompletionOct 1, 2009
Study CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 17.2 years ago

Interventions

Adjuvanted Multimeric-001 250 Mcgbiological

Multimeric-001 250 Mcgbiological

Phosphate Buffered salinebiological

Adjuvanted PBSbiological

Adjuvanted Multimeric-001 500 Mcgbiological

Multimeric-001 500 Mcgbiological

Multimeric-001 125 Mcgbiological